IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

IceCure Medical Ltd. (the "Company" or "IceCure" or "IceCure Medical") (NASDAQ: ICCM), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it intends to effect a one-for-thirty reverse split (the "Reverse Share Split") of the Company's ordinary shares, no par value per share, (the "Ordinary Shares"), as part of its proactive efforts to regain compliance with the Nasdaq $1.00 minimum bid price requir